ISRG Stock Recent News

ISRG's third-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales.

Major indexes faded late in Thursday's trading, with the Nasdaq Composite finishing up just .036%.

I reiterate a 'Sell' rating on Intuitive Surgical with a fair value of $350 per share due to its hefty valuation. The Da Vinci 5 robot rollout in mid-2025 is a major catalyst, with significant growth potential from innovative technology and positive surgeon feedback. Despite strong leadership and market position, ISRG's overvaluation and high WACC of 13% justify the 'Sell' rating.

Earnings of $5.40 per share for NFLX surged past the $5.09 in the Zacks consensus, demonstrating +45% growth year over year.

Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $1.84 per share, beating the Zacks Consensus Estimate of $1.65 per share. This compares to earnings of $1.46 per share a year ago.

Medical device maker Intuitive Surgical beat Wall Street estimates for third-quarter profit on Thursday, helped by strong demand for its surgical robots used in minimally invasive procedures, sending shares up 6% in extended trading.

Intuitive Surgical stock is flirting with its 50-day line as the robotic surgery behemoth approaches its third-quarter report late Thursday.

Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Intuitive Surgical (NASDAQ: ISRG) will report its Q3 2024 results on Thursday, October 17. We expect the company's revenues to come in at $2 billion and adjusted earnings to be $1.60 per share, reflecting a top-line above, but earnings slightly below the consensus estimate.

Besides Wall Street's top -and-bottom-line estimates for Intuitive Surgical (ISRG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.